Original Aspect and Future Administration in the Treatment of Heart Failure

Authors

  • Pintoo Sharma Department of Pharmaceutics, SGT College of Pharmacy, SGT University Gurgaon-Badli Road Chandu, Budhera, Gurugram-122505, Haryana, India
  • Mayank Phagna Department of Pharmaceutics, SGT College of Pharmacy, SGT University Gurgaon-Badli Road Chandu, Budhera, Gurugram-122505, Haryana, India
  • Reena Badhwar Department of Pharmaceutics, SGT College of Pharmacy, SGT University Gurgaon-Badli Road Chandu, Budhera, Gurugram-122505, Haryana, India

DOI:

https://doi.org/10.26452/fjphs.v2i4.327

Keywords:

Original Aspect, Administration, Treatment, Heart Failure

Abstract

Its control of cardiac arrest has also significantly changed over the last thirty years, leading to an improvement in life quality and results, a minimum of as patients with such a massively reduced left ventricular ejection fraction (HFrEF). It has been made feasible even by identifying different paths contributing to the formation and process like heart disease, which effectively focused on effective treatments. While several other possible targets, like diagnosis, have now been recognized, and the list is consistently widening. But instead of damage, like new and old therapeutical initiatives, they might provide much further advancements through diagnosis and those with HFrEF and broaden achievement towards the treating patients as for cardiac arrest to retained left ventricular ejection fraction (HFpEF) as well as other cardiac arrest phenotypic traits.

Downloads

Download data is not yet available.

Published

2022-12-07

How to Cite

Pintoo Sharma, Mayank Phagna, & Reena Badhwar. (2022). Original Aspect and Future Administration in the Treatment of Heart Failure. Future Journal of Pharmaceuticals and Health Sciences, 2(4), 311–320. https://doi.org/10.26452/fjphs.v2i4.327

Issue

Section

Review Articles